
    
      The study is conducted in two parts for both Cohort 1 and Cohort 2. Part I: Safety evaluation
      and efficacy exploration for MGD013. Part II: Efficacy expansion based on results from Part I
      to further evaluate the efficacy effect of MGD013.
    
  